760 related articles for article (PubMed ID: 23485835)
1. Is aspirin still the drug of choice for management of patients with peripheral arterial disease?
Poredos P; Jezovnik MK
Vasa; 2013 Mar; 42(2):88-95. PubMed ID: 23485835
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet therapy in peripheral artery disease.
Violi F; Basili S; Berger JS; Hiatt WR
Handb Exp Pharmacol; 2012; (210):547-63. PubMed ID: 22918746
[TBL] [Abstract][Full Text] [Related]
3. Antiplatelet and antithrombotic treatment of patients with peripheral arterial disease.
Poredos P; Jezovnik MK
Int Angiol; 2010 Feb; 29(1):20-6. PubMed ID: 20224527
[TBL] [Abstract][Full Text] [Related]
4. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic treatment in peripheral artery disease.
Olinic DM; Tataru DA; Homorodean C; Spinu M; Olinic M
Vasa; 2018 Feb; 47(2):99-108. PubMed ID: 29160765
[TBL] [Abstract][Full Text] [Related]
6. Do we have a unified consensus on antithrombotic management of PAD?
Poredos P; Antignani PL; Blinc A; Fras Z; Jezovnik MK; Fareed J; Mansilha A
Int Angiol; 2021 Jun; 40(3):229-239. PubMed ID: 33739074
[TBL] [Abstract][Full Text] [Related]
7. Review of aspirin and clopidogrel resistance in peripheral arterial disease.
Guirgis M; Thompson P; Jansen S
J Vasc Surg; 2017 Nov; 66(5):1576-1586. PubMed ID: 28893489
[TBL] [Abstract][Full Text] [Related]
8. [The basis of platelets: platelets and atherothrombosis: an understanding of the lack of efficacy of aspirin in peripheral arterial disease (PAD) and diabetic patients].
Drouet L; Bal dit Sollier C; Henry P
Drugs; 2010 Nov; 70 Suppl 1():9-14. PubMed ID: 20977287
[TBL] [Abstract][Full Text] [Related]
9. Aspirin in the secondary prevention of cardiovascular disease: an update of the APTC meta-analysis.
Lièvre M; Cucherat M
Fundam Clin Pharmacol; 2010 Jun; 24(3):385-91. PubMed ID: 19678849
[TBL] [Abstract][Full Text] [Related]
10. Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors.
Coccheri S
Drugs; 2010 May; 70(7):887-908. PubMed ID: 20426498
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic drugs for the secondary prevention of ischemic stroke.
Nenci GG; Goracci S
Ann Ital Med Int; 2000; 15(4):282-90. PubMed ID: 11202630
[TBL] [Abstract][Full Text] [Related]
12. Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
Mohler ER
Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S1-6. PubMed ID: 19213065
[TBL] [Abstract][Full Text] [Related]
13. Do the Effects of Secondary Prevention of Cardiovascular Events in PAD Patients Differ from Other Atherosclerotic Disease?
Poredos P; Jezovnik MK
Int J Mol Sci; 2015 Jun; 16(7):14477-89. PubMed ID: 26121301
[TBL] [Abstract][Full Text] [Related]
14. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?
Sigvant B; Henriksson M; Lundin F; Wahlberg E
Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):254-61. PubMed ID: 21450673
[TBL] [Abstract][Full Text] [Related]
15. Antithrombotic therapy in peripheral artery disease--antiplatelet therapy, anticoagulants, both or none.
Tangelder MJ; van Hattum ES
Thromb Haemost; 2010 Aug; 104(2):196-9. PubMed ID: 20508897
[No Abstract] [Full Text] [Related]
16. A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
Tangelder MJ; Nwachuku CE; Jaff M; Baumgartner I; Duggal A; Adams G; Ansel G; Grosso M; Mercuri M; Shi M; Minar E; Moll FL
J Endovasc Ther; 2015 Apr; 22(2):261-8. PubMed ID: 25809373
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet therapy: controversial aspects.
Coccheri S
Thromb Res; 2012 Mar; 129(3):225-9. PubMed ID: 22119155
[TBL] [Abstract][Full Text] [Related]
18. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.
Berger JS; Krantz MJ; Kittelson JM; Hiatt WR
JAMA; 2009 May; 301(18):1909-19. PubMed ID: 19436018
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotics in stable peripheral artery disease.
Kaplovitch E; Rannelli L; Anand SS
Vasc Med; 2019 Apr; 24(2):132-140. PubMed ID: 30799766
[TBL] [Abstract][Full Text] [Related]
20. Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD).
Shigematsu H; Nishibe T; Obitsu Y; Matsuzaki K; Ishida A; Miyata T; Shindo S; Hida K; Ohta T; Ando M; Kawasaki T; Yasugi T; Matsumoto T
Int Angiol; 2010 Apr; 29(2 Suppl):2-13. PubMed ID: 20357743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
